Enlivex Therapeutics Ltd.
Hedge Funds Holdings
Last updated:
Enlivex Therapeutics Ltd.‘s stocks are currently a part of 11 hedge funds’ portfolios, which represents 1.21% of the total amount of its stocks outstanding. This makes up a total of 222.15K shares of Enlivex Therapeutics Ltd.. Compared to the previous quarter, the number fell by -34.25% or -115.70K shares fewer. As for the holding position changes, 36.36% (4) of current hedge fund investors increased the number of shares held, 27.27% (3) of current holders sold a part of the shares held, and 9.09% (1) closed the holdings completely.
Hedge funds holding Enlivex Therapeutics Ltd. (Q1 2019 – Q1 2023)
| Q1 2019 | 1 |
|---|---|
| Q2 2019 | 2 |
| Q3 2019 | 4 |
| Q4 2019 | 4 |
| Q1 2020 | 6 |
| Q2 2020 | 7 |
| Q3 2020 | 4 |
| Q4 2020 | 11 |
| Q1 2021 | 22 |
| Q2 2021 | 19 |
| Q3 2021 | 19 |
| Q4 2021 | 20 |
| Q1 2022 | 23 |
| Q2 2022 | 20 |
| Q3 2022 | 18 |
| Q4 2022 | 20 |
| Q1 2023 | 11 |
Hedge funds changes in Enlivex Therapeutics Ltd. positions (Q1 2019 – Q1 2023)
| Q1 2019 | 1 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q2 2019 | 1 | 1 | 0 | 0 | 0 |
| Q3 2019 | 2 | 2 | 0 | 0 | 0 |
| Q4 2019 | 2 | 1 | 1 | 2 | -2 |
| Q1 2020 | 5 | 1 | 0 | 3 | -3 |
| Q2 2020 | 4 | 1 | 2 | 3 | -3 |
| Q3 2020 | 1 | 2 | 1 | 4 | -4 |
| Q4 2020 | 9 | 1 | 1 | 2 | -2 |
| Q1 2021 | 13 | 7 | 1 | 2 | -1 |
| Q2 2021 | 4 | 5 | 6 | 7 | -3 |
| Q3 2021 | 5 | 5 | 5 | 5 | -1 |
| Q4 2021 | 5 | 4 | 9 | 4 | -2 |
| Q1 2022 | 6 | 8 | 3 | 3 | 3 |
| Q2 2022 | 3 | 4 | 6 | 6 | 1 |
| Q3 2022 | 2 | 4 | 4 | 4 | 4 |
| Q4 2022 | 4 | 4 | 6 | 1 | 5 |
| Q1 2023 | 0 | 4 | 3 | 1 | 3 |
Hedge funds changes in Enlivex Therapeutics Ltd. stock options (Q1 2019 – Q1 2023)
| Q1 2019 | 0 | 0 |
|---|---|---|
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 300,000 | 801,000 |
| Q1 2021 | 1,011,000 | 2,605,000 |
| Q2 2021 | 286,000 | 1,417,000 |
| Q3 2021 | 1,651,000 | 1,398,000 |
| Q4 2021 | 664,000 | 457,000 |
| Q1 2022 | 56,000 | 311,000 |
| Q2 2022 | 532,000 | 196,000 |
| Q3 2022 | 2,405,000 | 552,000 |
| Q4 2022 | 1,212,192 | 207,480 |
| Q1 2023 | 0 | 0 |